Pemvidutide is the lead asset of Altimmune (NASDAQ: ALT), a small-cap biotech running one of the most watched dual-agonist peptide programs outside of Eli Lilly and Novo Nordisk. The molecule — also known as ALT-801 — is a once-weekly injectable peptide that activates both the GLP-1 receptor and the glucagon receptor in a deliberately balanced 1:1 ratio. In late 2024, pemvidutide delivered headline Phase 2b data showing 59 percent MASH resolution at its high dose, and the company is now positioning the asset for a pivotal Phase 3 program spanning both MASH and obesity. For a small biotech, the stakes are existential and the strategic logic is clean: find a niche Big Pharma is under-serving, and own it.
⚕️ Regulatory notice: Pemvidutide (ALT-801) is investigational. It has not been approved by the FDA, EMA, or any regulator for MASH, obesity, or any other indication. Phase 2b data in MASH and Phase 2 data in obesity have been reported; Phase 3 planning was underway as of early 2026. Nothing in this article is medical advice.
What Is Pemvidutide?
Pemvidutide is a synthetic peptide dual agonist of GLP-1 and glucagon receptors, engineered for once-weekly subcutaneous dosing. Structurally, it is a lipidated peptide — the lipid tail binds albumin in circulation, extending half-life the same way it does for semaglutide and tirzepatide.
What makes pemvidutide distinct is the balanced potency at each receptor. Competitor dual agonists like Boehringer Ingelheim's survodutide lean GLP-1-dominant. Altimmune designed pemvidutide so that glucagon activation would contribute meaningfully to the pharmacology rather than sit in the background. That choice has therapeutic consequences, especially in the liver.
If you are new to this drug class, start with our primers on what peptides are and how GLP-1 drugs work.
Mechanism: Why Add Glucagon?
GLP-1 agonists work primarily through appetite suppression, delayed gastric emptying, and improved insulin response. That mechanism drives weight loss but has limited direct effect on the liver.
Glucagon does something different. Glucagon receptor agonism increases hepatic fat oxidation and energy expenditure, essentially telling the liver to burn its own fat stores and telling the body as a whole to spend more calories at rest. Historically, glucagon's reputation as the "raise blood sugar" hormone made pharma nervous — you do not want a diabetes drug that worsens hyperglycemia. But when you pair glucagon agonism with GLP-1 (which stimulates insulin), the glucose-raising effect is neutralized while the fat-burning and energy-expenditure effects remain.
The payoff is especially compelling in metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH. MASH is a liver disease driven by fat accumulation, inflammation, and fibrosis. A drug that actively instructs the liver to burn its own triglycerides — on top of producing weight loss — is mechanistically better-suited to MASH than a pure GLP-1 agonist.
Our article on semaglutide and tirzepatide mechanisms walks through the full receptor biology.
Evidence and Clinical Trials
IMPACT Phase 2b — MASH (Harrison et al., 2024)
The IMPACT trial enrolled adults with biopsy-confirmed MASH and fibrosis stages F2–F3. Participants were randomized to pemvidutide 1.2 mg, 1.8 mg, or placebo, all once-weekly for 24 weeks, with biopsy at week 24.
Headline results reported in October 2024:
- MASH resolution without worsening of fibrosis: 59.1 percent at the 1.2 mg dose versus 19.1 percent on placebo.
- Fibrosis improvement by at least one stage without MASH worsening: numerically favorable but did not reach statistical significance at 24 weeks — a shorter biopsy window than most MASH trials use.
- Liver fat reduction: Approximately 75 percent relative reduction in liver fat at the high dose.
- Weight loss: ~5 percent at 24 weeks, with trajectory still falling at trial end.
The 59 percent MASH resolution figure is among the highest reported for any investigational MASH agent at a 24-week endpoint, and the magnitude of liver fat reduction is consistent with glucagon's expected hepatic mechanism.
MOMENTUM Phase 2 — Obesity (2024)
The MOMENTUM trial tested pemvidutide in adults with obesity over 48 weeks:
- Weight loss at 48 weeks, 2.4 mg dose: ~15.6 percent (placebo-adjusted ~12–13 percent).
- Lean mass preservation: A higher proportion of weight lost came from fat rather than lean mass, a point Altimmune emphasized in its investor communications given mounting concerns about muscle loss on GLP-1 drugs.
- Tolerability: Consistent with the GLP-1 class — nausea, vomiting, and diarrhea dominated, with discontinuation rates broadly in line with competitors.
Fifteen-plus percent weight loss places pemvidutide above first-generation semaglutide (~15 percent at 68 weeks in STEP 1) but below tirzepatide (~20 percent) and well below retatrutide's ~24 percent. In the MASH setting, however, weight loss is only part of the story — the liver-specific benefits matter independently.
Applications and Development Story
Altimmune is framing pemvidutide as a dual-indication opportunity — one asset addressing both MASH and obesity, with MASH as the differentiated lead indication where the glucagon arm matters most.
Strategically, that is sensible for a small biotech:
- MASH is a newly activated market after the 2024 approval of Madrigal's resmetirom (Rezdiffra), the first MASH-specific therapy. Pemvidutide would arrive with weight-loss benefits resmetirom lacks.
- Obesity is already a crowded market dominated by Novo Nordisk and Lilly; competing on raw weight loss is brutal. But competing on clean weight loss (more fat, less lean mass) or on MASH-plus-obesity combinations is a real niche.
- Altimmune has publicly discussed Phase 3 planning in both indications, with investigator and regulatory interactions through 2025.
The Competitive Landscape
Pemvidutide is one of three GLP-1/glucagon dual agonists with meaningful clinical data:
- Survodutide (Boehringer Ingelheim + Zealand Pharma): Phase 3 in obesity and Phase 2 data in MASH (~83 percent MASH resolution at 48 weeks at the top dose, though endpoints differed).
- Retatrutide (Eli Lilly): A triple agonist of GLP-1, GIP, and glucagon receptors with Phase 2 weight loss of ~24 percent and strong MASH and liver fat data. See our deep dive on retatrutide.
- Mazdutide (Innovent / Eli Lilly China): GLP-1/glucagon dual agonist approved in China for obesity in 2025.
Pemvidutide's niche is being the best balanced dual agonist from a smaller biotech, with MASH-first positioning.
Connection to the Broader Peptide Ecosystem
Pemvidutide sits at the intersection of two trends reshaping the peptide industry. First, the move beyond mono-agonists toward multi-receptor peptides — a path pioneered by tirzepatide's GIP/GLP-1 dual mechanism and now extending to triple agonists. Second, the redirection of obesity drugs into adjacent metabolic diseases (MASH, heart failure with preserved ejection fraction, chronic kidney disease, obstructive sleep apnea, Alzheimer's).
Smaller biotechs like Altimmune cannot out-spend Novo or Lilly on raw obesity indications. But they can pick a flanking mechanism (glucagon), pick a secondary indication where that mechanism differentiates (MASH), and generate Phase 2 data strong enough to attract partnership interest or justify an independent Phase 3. That playbook — which is essentially what Zealand executed with Boehringer — is the one Altimmune is following.
Manufacturing remains a bottleneck. Once-weekly peptides like pemvidutide rely on solid-phase peptide synthesis at scale, and the global peptide CDMO capacity shortage described in our peptide CDMO bottleneck article applies to pemvidutide too.
Limitations and Lessons
- Short-duration MASH biopsy data. The 24-week IMPACT readout is shorter than most MASH trials, which typically biopsy at 52 weeks. That favors the MASH resolution endpoint (faster read-through) but disadvantages the fibrosis endpoint (fibrosis takes longer to improve).
- GI tolerability is a ceiling. Like every GLP-1 drug, pemvidutide discontinuations on the top dose were non-trivial. Titration schedules matter enormously.
- Small-biotech execution risk. Phase 3 trials in MASH are expensive (~$300M+) and logistically demanding. Altimmune's market cap has swung dramatically around data readouts, and the company will likely need partnership capital or a major dilutive financing to run a proper Phase 3 in obesity.
- Competitive pressure from retatrutide. If Lilly's triple agonist delivers similar MASH benefits with superior weight loss, pemvidutide's positioning narrows.
- Liver enzyme monitoring. Glucagon agonism carries a theoretical risk of elevating transaminases; trial data must continue to demonstrate clean liver safety.
FAQ
What is the difference between pemvidutide and survodutide?
Both are GLP-1/glucagon dual agonists. Pemvidutide is more balanced between the two receptors; survodutide leans slightly GLP-1-dominant and is being developed by Boehringer Ingelheim at a larger scale.
Is pemvidutide approved?
No. It is investigational in Phase 2b (MASH) and Phase 2 (obesity), with Phase 3 planning underway as of early 2026.
How does pemvidutide compare to Ozempic?
Ozempic (semaglutide) is a pure GLP-1 agonist. Pemvidutide adds glucagon agonism, which provides additional liver-specific fat burning and energy expenditure on top of the GLP-1 effects.
Why does adding glucagon help in MASH?
Glucagon activation increases hepatic fat oxidation and energy expenditure, directly addressing the liver-fat accumulation that drives MASH. GLP-1 alone reduces liver fat indirectly through weight loss.
Does pemvidutide cause muscle loss?
Altimmune has presented data suggesting more favorable lean-mass preservation compared with pure GLP-1 comparators, though direct head-to-head data are limited. See our article on GLP-1 and muscle loss.
Who makes pemvidutide?
Altimmune (NASDAQ: ALT), a US-based clinical-stage biotech.
